Literature DB >> 21514967

Suppression of inflammation response by a novel A₃ adenosine receptor agonist thio-Cl-IB-MECA through inhibition of Akt and NF-κB signaling.

Hak-Sun Lee1, Hwa-Jin Chung, Hyuk Woo Lee, Lak Shin Jeong, Sang Kook Lee.   

Abstract

Adenosine, a purine nucleoside, is released from metabolically active cells into extracellular space and plays an important role in various pathophysiological processes. Adenosine regulates many biological responses including inflammation by the interaction with their receptors such as A₁, A(2A), A(2B), and A₃. Especially, A₃ adenosine receptor (A₃AR) is considered to be expressed in macrophage cells. To the end, A₃AR agonists have been reported to have an anti-inflammatory activity. In our continuous efforts to develop new anti-inflammatory agents, we found a novel adenosine analog, 2-chloro-N⁶-(3-iodobenzyl)-4'-thioadenosine-5'-N-methyluronamide (thio-Cl-IB-MECA), was a potent human A₃AR agonist. The study was designed to investigate whether thio-Cl-IB-MECA has an anti-inflammatory potential in mouse macrophage RAW 264.7 cells and mouse sepsis model in vivo. Thio-Cl-IB-MECA exhibited an effective anti-inflammatory activity. The expression of pro-inflammatory biomarkers including inducible nitric oxide synthase (iNOS), interleukin-1β (IL-1β), and tumor necrosis factor (TNF-α) was suppressed by the treatment of thio-Cl-IB-MECA in the protein and mRNA levels in lipopolysaccharide (LPS)-stimulated mouse macrophage RAW 264.7 cells. Further examination revealed that thio-Cl-IB-MECA inhibited LPS-induced phosphatidylinositol 3-kinase (PI3 kinase)/Akt activation, NF-kB binding activity, and β-catenin expression. In addition, in in vivo LPS-induced mouse endotoxemia model, thio-Cl-IB-MECA exerted the increase of survival rate compared to vehicle-treated mouse. The analysis of the protein levels of iNOS, IL-1β, and TNF-α was also suppressed by the compound-treated groups in lung tissues. These results suggest that thio-Cl-IB-MECA might have an anti-inflammatory activity through the inhibition of pro-inflammatory cytokine expression by modulating PI3K/Akt and NF-κB signaling pathways.
Copyright © 2011 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21514967     DOI: 10.1016/j.imbio.2011.03.008

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  12 in total

Review 1.  Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases.

Authors:  Bruce N Cronstein; Michail Sitkovsky
Journal:  Nat Rev Rheumatol       Date:  2016-11-10       Impact factor: 20.543

Review 2.  A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy.

Authors:  Kenneth A Jacobson; Stefania Merighi; Katia Varani; Pier Andrea Borea; Stefania Baraldi; Mojgan Aghazadeh Tabrizi; Romeo Romagnoli; Pier Giovanni Baraldi; Antonella Ciancetta; Dilip K Tosh; Zhan-Guo Gao; Stefania Gessi
Journal:  Med Res Rev       Date:  2017-07-06       Impact factor: 12.944

3.  Subtle Chemical Changes Cross the Boundary between Agonist and Antagonist: New A3 Adenosine Receptor Homology Models and Structural Network Analysis Can Predict This Boundary.

Authors:  Yoonji Lee; Xiyan Hou; Jin Hee Lee; Akshata Nayak; Varughese Alexander; Pankaz K Sharma; Hyerim Chang; Khai Phan; Zhan-Guo Gao; Kenneth A Jacobson; Sun Choi; Lak Shin Jeong
Journal:  J Med Chem       Date:  2021-08-26       Impact factor: 8.039

4.  Interferon-γ: Promising therapeutic target in atherosclerosis.

Authors:  Joe We Moss; Dipak P Ramji
Journal:  World J Exp Med       Date:  2015-08-20

Review 5.  Atherosclerosis and interferon-γ: new insights and therapeutic targets.

Authors:  Iryna Voloshyna; Michael J Littlefield; Allison B Reiss
Journal:  Trends Cardiovasc Med       Date:  2013-08-02       Impact factor: 6.677

Review 6.  Cytokines: roles in atherosclerosis disease progression and potential therapeutic targets.

Authors:  Joe We Moss; Dipak P Ramji
Journal:  Future Med Chem       Date:  2016-06-30       Impact factor: 3.808

7.  Activation of adenosine A3 receptor alleviates TNF-α-induced inflammation through inhibition of the NF-κB signaling pathway in human colonic epithelial cells.

Authors:  Tianhua Ren; Yumei Qiu; Weiyun Wu; Xiao Feng; Shicai Ye; Zhuang Wang; Ting Tian; Yanting He; Caiyuan Yu; Yu Zhou
Journal:  Mediators Inflamm       Date:  2014-04-22       Impact factor: 4.711

8.  A₃ adenosine receptor allosteric modulator induces an anti-inflammatory effect: in vivo studies and molecular mechanism of action.

Authors:  Shira Cohen; Faina Barer; Sara Bar-Yehuda; Adriaan P IJzerman; Kenneth A Jacobson; Pnina Fishman
Journal:  Mediators Inflamm       Date:  2014-10-13       Impact factor: 4.711

Review 9.  Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension.

Authors:  Allan K N Alencar; Guilherme C Montes; Eliezer J Barreiro; Roberto T Sudo; Gisele Zapata-Sudo
Journal:  Front Pharmacol       Date:  2017-12-04       Impact factor: 5.810

10.  Activation of Adenosine A3 Receptor Inhibits Microglia Reactivity Elicited by Elevated Pressure.

Authors:  Joana Ferreira-Silva; Inês D Aires; Raquel Boia; António Francisco Ambrósio; Ana Raquel Santiago
Journal:  Int J Mol Sci       Date:  2020-09-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.